Newsq

Vaccine controls HIV infection
Enlarge image

ResearchSpainFrance

Vaccine controls HIV infection

03.01.2013 - Spanish and French researchers have found a therapeutic vaccine strategy to boost the immune response to HIV.

A therapeutic vaccine that uses heat-inactivated HIV appears to boost the immune response to the virus in people, reports Science Translational Medicine. The findings pave the way for the development of vaccines that could potentially control HIV replication without the need for life-long antiretroviral medication. The vaccine is made from treated dendritic cells or DCs.

When a microorganism like HIV invades the body, cells called phagocytes chop up the virus and break it into small fragments. Some of these pieces find their way into the membranes of DCs. The DCs then present the pieces of HIV to lymphocytes, white blood cells that then launch a specific immune response against the virus. The problem is that DCs can also carry a part of the infectious virus on their outer membrane. Consequently, the white blood cells can get infected and die instead of developing an immune response.

To avoid this problem, Felipe García from University of Barcelona and colleagues from CRNS Paris primed the DCs of 36 patients with heat-inactivated HIV and then delivered the DCs back into patients as a therapeutic vaccine. The exposure to inactivated HIV allows the DCs to deliver their message to the white blood cells without harming them. The researchers found that vaccine was able to stimulate a noticeable degree of immune response against HIV, and that higher responses correlated with better control of virus replication. However, it is not yet clear how much of an immune response is needed to make an effective vaccine. Importantly, the vaccine appeared to be safe and well-tolerated. The results offer evidence that future HIV vaccines could help control the virus.

Earlier in December another research team from Barcelona had presented a different strategy to prevent HIV infection of human CD4 lymphocytes. By blocking HIV entry into DCs they were able to prevent CD4 cells from viral invasion.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/vaccine-controls-hiv-infection.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF21.8%
  • MAGFORCE6.90 EUR10.8%
  • BB BIOTECH140.45 EUR5.1%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.85 EUR-19.5%
  • VITA 343.75 EUR-17.6%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR188.4%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-68.1%
  • MERCK KGAA66.20 EUR-43.4%

No liability assumed, Date: 26.08.2014